Matthew Schabacker Power - 02 Mar 2026 Form 4/A - Amendment Insider Report for CONMED Corp (CNMD)

Role: VP GM Advanced Surgical
Signature: /s/ Thomas Fistek for Matthew Schabacker by Power of Attorney
Issuer symbol: CNMD
Transactions as of: 02 Mar 2026
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 18 Mar 2026, 14:04:27 UTC
Date Of Original Report: 04 Mar 2026
Previous filing: 01 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Schabacker Matthew	VP GM Advanced Surgical	C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO	/s/ Thomas Fistek for Matthew Schabacker by Power of Attorney	18 Mar 2026	0002066553

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CNMD	RSUs (Restricted Stock Units)	Award		+17,471		$0.000000^*	17,471	02 Mar 2026	Common Stock	17,471	$0.000000	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.
F2	This Form 4/A is filed solely to correct the amount of RSUs granted. A special award of 7,644 shares was awarded in addition to the originally reported 9,827 shares for a total of 17,471 RSUs granted.

Content

Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.

This Form 4/A is filed solely to correct the amount of RSUs granted. A special award of 7,644 shares was awarded in addition to the originally reported 9,827 shares for a total of 17,471 RSUs granted.